CD80 and inflammatory bowel disease: As described above, engagement of Cd80/86 by sCtla-4-Ig effectively suppressed T cell activation in vitro (Figure 7B), indicating that sCtla-4-Ig holds promise as a potential intervention for IBD-like phenotype.